Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542841 · ClinicalTrials.gov registry record · NA
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency
A NA study of 21-Hydroxylase Deficiency, sponsored by Maria I. New.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
- 3
- Study locations
NCT00542841: Completed NA study of 21-Hydroxylase Deficiency, sponsored by Maria I. New.
NCT00542841 is a NA study of 21-Hydroxylase Deficiency that has completed, run by Maria I. New. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00542841, a NA study of 21-Hydroxylase Deficiency, has completed, sponsored by Maria I. New.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
- 3
- Study locations
Study Summary
Congenital adrenal hyperplasia (CAH) is a genetic disorder that affects the amount of steroids that the body forms. The most common form of CAH is 21-hydroxylase deficiency (21OHD), which leads to cortisol deficiency. This, in turn, causes the development of mature masculine characteristics in newborn, prepubescent, and grown females and in prepubescent males. 21OHD is known to be caused by the mutation of a specific gene. However, symptom severity among people with 21OHD varies, and adults seem to be less affected than children. This study will examine participants' DNA to determine what other genes may affect the severity of 21OHD and may make the disease milder in adults than in children.
Conditions Studied
Interventions
- PROCEDURE Hydrocortisone withdrawal
Study Locations (3)
New York
- Mount Sinai School of Medicine - New York
Texas
- University of Texas Southwestern Medical Center - Dallas
São Paulo
- University of Sao Paolo - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | NA |
What the finished NCT00542841 record still lists
NCT00542841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with 21-Hydroxylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Hydrocortisone withdrawal is the first listed.
NCT00542841 reports a single indexed study location in New York, Texas, São Paulo.
Frequently Asked Questions
What is clinical trial NCT00542841 about?
NCT00542841 is a clinical study titled "Examining Genetic Differences Among People With 21-Hydroxylase Deficiency". Congenital adrenal hyperplasia (CAH) is a genetic disorder that affects the amount of steroids that the body forms. The most common form of CAH is 21-hydroxylase deficiency (21OHD), which leads to cortisol deficiency. This, in turn, causes the development of mature masculine characteristics in newbo...
What is the current status of trial NCT00542841?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2007-08. Estimated completion is 2009-03.
What conditions does trial NCT00542841 study?
This clinical trial studies the following conditions: 21-Hydroxylase Deficiency.
What interventions are being tested in trial NCT00542841?
The interventions under investigation include: Hydrocortisone withdrawal (PROCEDURE).
Who is sponsoring clinical trial NCT00542841?
This trial is sponsored by Maria I. New, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00542841 being conducted?
This trial has 3 study locations across New York, Texas, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for 21-Hydroxylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00542841's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia